Today
+1.16%
5 Days
-1.29%
1 Month
-2.35%
6 Months
-18.83%
Year to Date
-18.83%
1 Year
-51.99%
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
TradingKey - Just two months into their weight-loss drug partnership, Novo Nordisk (NVO) announced on Monday, June 23, that it is terminating its collaboration with telehealth company Hims&Hers (HIMS). The move sent shockwaves through the market, with shares of the so-called "AI + healthcare" growth
Though oncology remains the largest therapeutic area in the pharmaceutical industry, the weight management field has caught fire in the past few years. Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest...
.jpg)
Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.
.jpg)
TradingKey - With the appointment of vaccine skeptic Robert F. Kennedy Jr. (RFK Jr.) as U.S. Secretary of Health and Human Services, coupled with the forc
March 13 (Reuters) - U.S. stock index futures declined on Thursday as investors closely monitored a stopgap government funding bill amid escalating slowdown fears driven by President Donald Trump's chaotic tariff policies. .N
TradingKey - While Wednesday's CPI data came in below expectations, alleviating some market fears, intra-day trading remained volatile, indicating that investors are still seeking more data for further assessment.
